medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2017, Number 2

<< Back Next >>

Rev Invest Clin 2017; 69 (2)

General Overview and Treatment Recommendations for Young Women with Breast Cancer

Ribnikar D, Ratoša I, Perhavec A, Amir E

Language: English
References: 150
Page: 77-93
PDF size: 146.11 Kb.


ABSTRACT

Breast cancer in young women is a complex disease to manage due to its biological heterogeneity and special issues related to toxicity of different treatment strategies. Defining a cut-off for young age has been challenging since it is not clear whether the prognostic effect of age is continuously variable or whether there are certain thresholds at which the prognosis changes (e.g. those ‹ 50 years of age or ≤ 35 years of age). In this review article, we define young patients as those being premenopausal. In addition, we discuss the most recent data of the biological diversity of breast cancer arising in premenopausal patients and current treatment modalities in early and advanced settings. Survivorship, with special emphasis on the importance of early supportive care, is also discussed.


REFERENCES

  1. WHO. Women and health. 2009. Available at: http://www.who.int/ gender/women_health_report/full_report_20091104_en.pdf

  2. Villarreal-Garza C, Aguila C, Magallanes-Hoyos MC, et al. Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist. 2013;18:1298-306.

  3. Collins LC, Marotti JD, Gelber S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012;131:1061-6.

  4. Partridge AH, Hughes ME, Ottesen RA, et al. The effect of age on delay in diagnosis and stage of breast cancer. Oncologist. 2012;17:775-82.

  5. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134:459-78.

  6. Cardoso F, Loibl S, Pagani O, et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer. 2012;48:3355-77.

  7. Partridge AH, Pagani O, Abulkhair O, et al. First international consensus guidelines for breast cancer in young women (BCY1). Breast. 2014;23:209-20.

  8. Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ. 2000;320:4748.

  9. Gabriel CA, Domchek SM. Breast cancer in young women. Breast Cancer Res. 2010;12:212.

  10. De La Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR. Age as prognostic factor in premenopausal breast carcinoma. Lancet. 1993;341:1039-43.

  11. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75:305-9.

  12. Smith IE, Dowsett M, Yap Y-S, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: Caution and suggested guidelines. J Clin Oncol. 2006;24:2444-7.

  13. World Health Organization. Tech Rep Ser Res menopause Geneva Switz WHO. 1991;670.

  14. National Comprehensive Cancer Network practice guidelines in oncology. 2005. https://www.nccn.org/professionals/physician_ gls/pdf/breast.pdf

  15. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-92.

  16. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-802.

  17. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131-9.

  18. Cooper GS, Baird DD, Darden FR. Measures of menopausal status in relation to demographic, reproductive, and behavioral characteristics in a population-based study of women aged 35-49 years. Am J Epidemiol. 2001;153:1159-65.

  19. Delrio G, De Placido S, Pagliarulo C, et al. Hypothalamic-pituitaryovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. Tumori. 1986;72:53-61.

  20. Lum SS, Woltering EA, Fletcher WS, Pommier RF. Changes in serum estrogen levels in women during tamoxifen therapy. Am J Surg. 1997;173:399-402.

  21. Amir E, Seruga B, Freedman O, Clemons M. Amenorrhoea, menopause, and endocrine therapy for breast cancer. BMJ. 2009; 339:b4261.

  22. Vital-Reyes V, Tellez-Velasco S, Chhieng D, Grizzle W, Reyes- Fuentes A. Spontaneous pregnancy in a woman with premature ovarian failure: a case report. J Reprod Med. 2004;49:989-91.

  23. Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol Off J Eur Soc Med Oncol. 2002;13:273-9.

  24. Han W, Kang SY, Korean Breast Cancer Society. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat. 2010;119:193-200.

  25. Copson E, Eccles B, Maishman T, et al. Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: The POSH Study. J Natl Cancer Inst. 2013;105:978-88.

  26. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790-800.

  27. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206-23.

  28. Koboldt DC, Fulton RS, McLellan MD, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.

  29. Azim HA, Michiels S, Bedard PL, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 2012;18:1341-51.

  30. Sabiani L, Houvenaeghel G, Heinemann M, et al. breast cancer in young women: Pathologic features and molecular phenotype. Breast. 2016;29:109-16.

  31. Azim HA, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16:427.

  32. Rudra S, Yu DS, Yu ES, Switchenko JM, Mister D, Torres MA. Locoregional and distant recurrence patterns in young versus elderly women treated for breast cancer. Int J Breast Cancer. 2015;2015:213123.

  33. Seneviratne S, Lawrenson R, Harvey V, et al. Stage of breast cancer at diagnosis in New Zealand: impacts of socio-demographic factors, breast cancer screening and biology. BMC Cancer. 2016;16:129.

  34. Paluch-Shimon S, Wolf I, Sadetzki S, et al. Association between very young age and adverse characteristics of breast cancer at presentation amongst Israeli women. Am J Clin Oncol. 2011;34:219-22.

  35. Johnson RH, Chien FL, Bleyer A, et al. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA. 2013;309:800.

  36. Hung M-H, Liu C-Y, Shiau C-Y, et al. Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients. PLoS One. 2014;9:e89389.

  37. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271-7.

  38. Ernst MF, van de Poll-Franse LV, Roukema JA, et al. Trends in the prognosis of patients with primary metastatic breast cancer diagnosed between 1975 and 2002. Breast. 2007;16:344-51.

  39. van de Vijver MJ, He YD, van ’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.

  40. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-26.

  41. Anders CK, Acharya CR, Hsu DS, et al. Age-Specific Differences in Oncogenic Pathway Deregulation Seen in Human Breast Tumors. Wu X, editor. PLoS One. 2008;3:e1373.

  42. Young S, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9:86.

  43. Criscitiello C, Azim HA, Schouten PC, Linn SC, Sotiriou C. Understanding the biology of triple-negative breast cancer. Ann Oncol. 2012;23(Suppl 6):vi13-18.

  44. Azim H, Nguyen B, Brohee S, Zoppoli G, Sotiriou C. Genomic aberrations in young and elderly breast cancer patients. BMC Med. 2015;13:266.

  45. Liu Z, Merkurjev D, Yang F, Li W, Oh S, Friedman MJ. Enhancer activation requires trans-recruitment of a mega transcription factor complex. Cell. 2014;159:358-73.

  46. Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: Cells GATA have it! J Cell Physiol. 2010;222:42-9.

  47. Adomas AB, Grimm SA, Malone C, Takaku M, Sims JK, Wade PA. Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover. BMC Cancer. 2014;14:278.

  48. Anders CK, Johnson R, Litton J. BC before age 40 years. Semin Oncol. 2009;36:237-49.

  49. Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016;34:3308-14.

  50. Clarke M, Coates AS, Darby SC. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level metaanalysis of randomized trials. Lancet. 2008;371:29-40.

  51. Huober J, von Minckwitz G, Denkert C. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological BC phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat. 2010;124:133-40.

  52. Partridge AH, Gelber S, Piccart-Gebhart MJ, et al. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol. 2013;31:2692-8.

  53. Paluch-Shimon S, Pagani O, Partridge AH, et al. Second international consensus guidelines for breast cancer in young women (BCY2). Breast. 2016;26:87-99.

  54. Vila J, Gandini S, Gentilini O. Overall survival according to type of surgery in young (≤40 years) early breast cancer patients: A systematic meta-analysis comparing breast-conserving surgery versus mastectomy. Breast. 2015;24:175-81.

  55. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227-32.

  56. Kroman N, Holtveg H, Wohlfahrt J, et al. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer. 2004;100:688-93.

  57. de Bock GH, van der Hage JA, Putter H, Bonnema J, Bartelink H, van de Velde CJ. Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: Long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer. 2006;42:351-6.

  58. Botteri E, Bagnardi V, Rotmensz N, et al. Analysis of local and regional recurrences in breast cancer after conservative surgery. Ann Oncol. 2010;21:723-8.

  59. Komoike Y, Akiyama F, Iino Y, et al. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer. Cancer. 2006;106:35-41.

  60. van der Sangen MJ, van de Wiel FM, Poortmans PM, et al. Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged ≤40 years. Breast Cancer Res Treat. 2011;127:207-15.

  61. Aalders KC, Postma EL, Strobbe LJ, et al. Contemporary locoregional recurrence rates in young patients with early-stage breast cancer. J Clin Oncol. 2016;34:2107-14.

  62. Bartelink H, Horiot J-C, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast Cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 Trial. J Clin Oncol. 2007;25(22):3259-65.

  63. Plichta JK, Rai U, Tang R, et al. Factors associated with recurrence rates and long-term survival in women diagnosed with breast cancer ages 40 and younger. Ann Surg Oncol. 2016;23:3212-20.

  64. Gradishar WJ, Robert CH, Anderson BO, et al. NCCN Guidelines Version 2.2016 Breast Cancer Panel Members NCCN Evidence Blocks TM. 2016. https://www.nccn.org/professionals/physician_ gls/pdf/breast_blocks.pdf

  65. Hieken TJ, Boolbol SK, Dietz JR. Nipple-sparing mastectomy: Indications, contraindications, risks, benefits, and techniques. Ann Surg Oncol. 2016;23:3138-44.

  66. Toesca A, Peradze N, Manconi A, et al. Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. Breast. 2017;31:51-6.

  67. Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year Breast Cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707-16.

  68. EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year Breast Cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127-35.

  69. van Laar C, van der Sangen MJ, Poortmans PM, et al. Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. Eur J Cancer. 2013;49:3093-101.

  70. Bosma SCJ, van der Leij F, van Werkhoven E, et al. Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period. Breast Cancer Res Treat. 2016;156:391-400.

  71. Recht A, Comen EA, Fine RE, et al. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Pract Radiat Oncol. 2016;6:e219-34.

  72. Bartelink H. The changing landscape in radiotherapy for breast cancer: Lessons from long term follow-up in some European breast cancer trials. Radiother Oncol. 2016;121:348-56.

  73. Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307-16.

  74. Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373:317-27.

  75. Budach W, Bölke E, Kammers K, Gerber PA, Nestle-Krämling C, Matuschek C. Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trialsan update. Radiat Oncol. 2015;10:258.

  76. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087-106.

  77. Brackstone M, Fletcher GG, Dayes IS, et al. Locoregional therapy of locally advanced breast cancer: a clinical practice guideline. Curr Oncol. 2015;22(Suppl 1):S54-66.

  78. Poortmans PM, Whelan TJ. Locoregional treatment in early stage breast cancer: More evidence and yet more questions? J Clin Oncol. 2015;27:689-91.

  79. Poortmans P. Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate. Lancet. 2014;383:2104-6.

  80. Kunkler IH, Canney P, van Tienhoven G, Russell NS, MRC/EORTC (BIG 2-04) SUPREMO Trial Management Group. Elucidating the role of chest wall irradiation in “intermediate-risk” breast cancer: the MRC/EORTC SUPREMO trial. Clin Oncol (R Coll Radiol). 2008;20:31-4.

  81. Thorsen LB, Offersen BV, Danř H, et al. DBCG-IMN: A populationbased cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. 2016;34:314-20.

  82. Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8-30.

  83. Yildirim E, Berberoglu U. Local recurrence in breast carcinoma patients with T1-2 and 1-3 positive nodes: Indications for radiotherapy. Eur J Surg Oncol. 2007;33:28-32.

  84. Su Y-L, Li S-H, Chen Y-Y, et al. Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis. Radiol Oncol. 2014;48:314-22.

  85. Ashworth A, Kong W, Whelan T, Mackillop WJ. A populationbased study of the fractionation of postlumpectomy breast radiation therapy. Int J Radiat Oncol. 2013;86:51-7.

  86. Nguyen K, Mackenzie P, Allen A, et al. Breast interest group faculty of radiation oncology: Australian and New Zealand patterns of practice survey on breast radiotherapy. J Med Imaging Radiat Oncol. 2016. [Epub ahead of print].

  87. Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year followup results of two randomised controlled trials. Lancet Oncol. 2013;14:1086-94.

  88. Bekelman JE, Sylwestrzak G, Barron J, et al. Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008-2013. JAMA. 2014;312:2542.

  89. Whelan TJ, Pignol J-P, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362:513-20.

  90. Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006;7:467-71.

  91. Caudrelier J-M, Truong PT. Role of hypofractionated radiotherapy in breast locoregional radiation. Cancer/Radiothérapie. 2015;19:241-7.

  92. DBCG; Danish Breast Cancer Cooperative Group. The SKAGEN Trial 1 Moderately hypofractionated loco-regional adjuvant radiation therapy of early breast cancer combined with a simultaneous integrated boost in patients with an indication for boost: DBCG HYPO II, a randomised clinically controlled trial. 2015. p. 1-33. Available from: www.dbcg.dk/

  93. Ain Shams University. Conventional Versus Hypofractionated Radiotherapy in Node Positive Breast Cancer. ClinicalTrials.gov Identifier: NCT02690636.

  94. Koulis TA, Phan T, Olivotto IA. Hypofractionated whole breast radiotherapy: current perspectives. Breast Cancer. 2015;7:363-70.

  95. Barry M, Kell MR. Radiotherapy and breast reconstruction: a meta-analysis. Breast Cancer Res Treat. 2011;127:15-22.

  96. Khan AJ, Rafique R, Zafar W, et al. Nation-scale adoption of shorter breast radiation therapy schedules can increase survival in resource constrained economies: Results from a Markov chain analysis. Int J Radiat Oncol. 2017;97:287-95.

  97. Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation with or without a boost for patients treated with breastconserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16:47-56.

  98. Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with wholebreast irradiation in stages I and II invasive breast cancer. J Clin Oncol. 2014;32:1507-15.

  99. Houssami N, Macaskill P, Luke Marinovich M, Morrow M. The Association of Surgical Margins and Local Recurrence in Women with Early-Stage Invasive breast cancer Treated with Breast-Conserving Therapy: A Meta-Analysis. Ann Surg Oncol. 2014;21:717-30.

  100. Brouwers PJ, van Werkhoven E, Bartelink H, et al. Factors associated with patient-reported cosmetic outcome in the Young Boost Breast Trial. Radiother Oncol. 2016;120:107-13.

  101. Tramm T, Mohammed H, Myhre S, et al. Development and validation of a gene profile predicting benefit of postmastectomy radiotherapy in patients with high-risk breast cancer: a study of gene expression in the DBCG82bc cohort. Clin Cancer Res. 2014;20:5272-80.

  102. Cheng SH, Horng C-F, Huang T-T, et al. An eighteen-gene classifier predicts locoregional recurrence in post-mastectomy breast cancer Patients. EBioMedicine. 2016;5:74-81.

  103. Torres-Roca JF, Fulp WJ, Caudell JJ, et al. Integration of a radiosensitivity molecular signature into the assessment of local recurrence risk in breast cancer. Int J Radiat Oncol Biol Phys. 2015;93:631-8.

  104. Vicini F, Shah C, Tendulkar R, et al. Accelerated partial breast irradiation: An update on published Level I evidence. Brachytherapy. 2016;15:607-15.

  105. NSABP B-39, RTOG 0413: A Randomized Phase III Study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clin Adv Hematol Oncol. 2006;4:719-21.

  106. Offersen BV, Boersma LJ, Kirkove C, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol. 2015;114:3-10.

  107. Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79:10-18.

  108. Smyth LM, Knight KA, Aarons YK, Wasiak J. The cardiac dosesparing benefits of deep inspiration breath-hold in left breast irradiation: a systematic review. J Med Radiat Sci. 2015;62:66-73.

  109. Taylor CW, Kirby a M. Cardiac side-effects from breast cancer radiotherapy. Clin Oncol (R Coll Radiol). 2015;27:621-9.

  110. Latty D, Stuart KE, Wang W, Ahern V. Review of deep inspiration breath-hold techniques for the treatment of breast cancer. J Med Radiat Sci. 2015;62:74-81.

  111. Bartlett FR, Colgan RM, Donovan EM, et al. Voluntary breath-hold technique for reducing heart dose in left breast radiotherapy. J Vis Exp. 2014;89.

  112. Conway JL, Conroy L, Harper L, et al. Deep inspiration breath-hold produces a clinically meaningful reduction in ipsilateral lung dose during locoregional radiation therapy for some women with rightsided breast cancer. Pract Radiat Oncol. 2016. [Epub ahead of print].

  113. Stovall M, Smith SA, Langholz BM, et al. Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE Study. Int J Radiat Oncol Biol Phys. 2008;72:1021-30.

  114. Grantzau T, Overgaard J. Risk of second non- breast cancer after radiotherapy for breast cancer: A systematic review and metaanalysis of 762,468 patients. Radiother Oncol. 2015;114:56-65.

  115. Hallam S, Govindarajulu S, Huckett B, Bahl A. BRCA1/2 mutation- associated breast cancer, wide local excision and radiotherapy or unilateral mastectomy: A systematic review. Clin Oncol (R Coll Radiol). 2015;27:527-35.

  116. Bernstein JL, Thomas DC, Shore RE, et al. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: A WECARE Study Report. Eur J Cancer. 2013;49:2979-85.

  117. Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer post-operative radiotherapy in patients with Li- Fraumeni syndrome. Radiat Oncol. 2010;5:104.

  118. Freedman RA, Partridge AH. Management of breast cancer in very young women. Breast. 2013;22:S176-9.

  119. Wolmark N, Wang J, Mamounas E, Project B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. Cancer Inst Monogr. 2001;30:96-102.

  120. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432-44.

  121. Lambertini M, Ceppi M, Cognetti F, et al. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. Eur J Cancer. 2017;71:34-42.

  122. Amir E, Ocana A, Freedman O, Clemons M, Seruga B. Chemotherapy: dose-dense treatment for triple-negative breast cancer. Nat Rev Clin Oncol. 2010;7:79-80.

  123. Anders CK, Zagar TM, Carey LA. The management of earlystage and metastatic triple-negative breast cancer: a review. Hematol Oncol Clin North Am. 2013;27:737-49.

  124. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer. CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13-21.

  125. von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15:747-56.

  126. Christinat A, Di Lascio S, Pagani O. Hormonal therapies in young breast cancer patients: when, what and for how long? J Thorac Dis. 2013;5(Suppl 1):S36-46.

  127. Iwata H, Masuda N, Sagara Y, et al. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer. Cancer. 2013;119: 704-13.

  128. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patientlevel meta-analysis of randomised trials. Lancet. 2011;378:771-84.

  129. Francis PA, Regan MM, Fleming GF. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:1672-3.

  130. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805-16.

  131. Azim HA, Saadeldeen A. Commentary on “aTTom”: long-term effects of continuing adjuvant Tamoxifen to 10 years. Chin Clin Oncol. 2014;3:7.

  132. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptorpositive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262-71.

  133. Gnant M, Mlineritsch B, Stoeger H, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015;26:313-20.

  134. Goel S, Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Goel S, editor. Cochrane Database Syst Rev. 2009;4:CD004562.

  135. LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369:1711-23.

  136. Bellet M, Gray KP, Francis PA, et al. Estrogen levels in premenopausal patients with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin plus exemestane or tamoxifen in the SOFT trial: SOFT-EST substudy. J Clin Oncol. 2014;32. [Abstract 585].

  137. Dowsett M, Folkerd E, Res BC. Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer. 2005;7:1-4.

  138. Ben-Aharon I, Vidal L, Rizel S, et al. Bisphosphonates in the adjuvant setting of breast cancer therapy: effect on survival – a systematic review and meta-analysis. J Clin Oncol. 2012;30. [Abstract 548].

  139. Cardoso F, Costa A, Senkus E, et al. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast. 2017;31:244-59.

  140. Tutt A, Ellis P, Kilbum L. TNT: a randomized phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 breast cancer. Cancer Res. 2015;75:S3-1.

  141. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO- 18): a randomised phase 2 study. Lancet Oncol. 2015;16:25-35.

  142. Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015;13:188.

  143. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33:244-50.

  144. Bantema-Joppe EJ, de Bock GH, Woltman-van Iersel M, et al. The impact of age on changes in quality of life among breast cancer survivors treated with breast-conserving surgery and radiotherapy. Br J Cancer. 2015;112:636-43.

  145. Ali A, Fergus K, Wright FC, Pritchard KI, Kiss A, Warner E. The impact of a breast cancer diagnosis in young women on their relationship with their mothers. Breast. 2014;23:50-5.

  146. Arčs I, Lebel S, Bielajew C. The impact of motherhood on perceived stress, illness intrusiveness and fear of cancer recurrence in young breast cancer survivors over time. Psychol Health. 2014;29:651-70.

  147. Grabiak BR, Bender CM, Puskar KR. The impact of parental cancer on the adolescent: an analysis of the literature. Psychooncology. 2007;16:127-37.

  148. Paalman CH, van Leeuwen FE, Aaronson NK, et al. Employment and social benefits up to 10 years after breast cancer diagnosis: a population-based study. Br J Cancer. 2016;114:81-7.

  149. Ekwueme DU, Trogdon JG, Khavjou OA, Guy GP. Productivity costs associated with breast cancer among survivors aged 18- 44 years. Am J Prev Med. 2016;50:286-94.

  150. Easley J, Miedema B. Rehabilitation after breast cancer: Recommendations from young survivors. Rehabil Nurs. 2012;37:163-70.




2020     |     www.medigraphic.com